Liquid Biopsies for early detection of lung cancer progression
In cancer patients, circulating tumor DNA (ctDNA) isolated from blood plasma offers a molecular glimpse of disease status. Here, we demonstrated that ctDNA analysis using next generation sequencing assays can detect early molecular disease progression prior to clinical evaluations by conventional imaging modalities in ALK+ non-small cell lung cancer.
Dying cells shed DNA into the blood where it is called circulating tumor DNA (ctDNA). ctDNA fragments harbor molecular alterations that are found in the tumor genome such as gene mutations, copy number variations, and other genomic features, which can be identified using next-generation sequencing (NGS) technologies.
EML4-ALK gene fusions (ALK+) occur in about 5% of lung adenocarcinomas1. Although multiple approved ALK tyrosine kinase inhibitors (TKI) can significantly improve response rates and prolong patient survival, most tumors eventually develop therapy resistance and progress. The molecular alterations associated with these processes include gene amplification, point mutations within the exon coding for the ALK tyrosine kinase domain, and activation of bypass signaling pathways that include MET, EGFR, and KIT2-4. Since tissue is rarely available from relapses, minimally invasive liquid biopsies can be used for ALK+ disease monitoring and selection of alternative therapy options. Previously5, we applied two NGS assays for evaluating ctDNA in the plasma of ALK+ non-small cell lung cancer (NSCLC) patients. The first approach was through a targeted NGS (tNGS) panel that identifies single nucleotide variations (SNVs), copy number changes, and fusions in few selected cancer-relevant genes. The second NGS assay involved shallow whole genome sequencing (sWGS)6 to evaluate regional copy number changes (CNVs).
In our study, we extended this ALK+ NSCLC cohort to multiple longitudinal samples and asked whether ctDNA detection using tNGS and sWGS could precede disease progression as identified by computed tomography (CT) imaging. We were able to confirm the presence of the ALK fusion or mutations in 51% (22/43) of patients. We also observed alterations in other cancer-relevant genes including MET, EGFR, KRAS, KIT, and RET. In patients with detectable ALK alterations, we found that the variant allele frequencies (VAFs) of ALK mutation or fusion increased upon disease progression. We observed the opposite trend in samples collected post therapy change, possibly indicating therapy response. Many cases without detectable ALK alterations either had stable disease or intracranial progression, which could explain the low ctDNA amount in the plasma. Most importantly, we were able to identify 21 cases of early molecular progression in 19 (44%) patients. This means, that a significant change in VAF or CNVs was already present prior to a clinically detectable progression. The lead times ranged from 20 to 638 days, with a median of 88 days. The majority of cases with identified lead times were patients with detectable ALK alterations which most likely indicated high ctDNA levels, suggesting that lead time calling is most beneficial for patients with elevated ctDNA levels. Interestingly, lead times correlated with longer therapy durability, which could be relevant in the clinical setting as newer ALK TKIs demonstrate progression-free survival of at least two years.
There are numerous advantages in implementing liquid biopsy approaches for disease monitoring. First and foremost are the minimally invasive blood draws that could supplant tissue rebiopsies that are the current standard for the identification of actionable drug targets (Figure 1). For solid tumors, this approach also minimizes the cumulative radiation exposure from regular CT imaging. Early detection of resistance mutations could prompt clinicians to halt ineffective treatments and facilitate a therapy switch. Nonetheless, the data that we present is not without caveats and limitations. Our study has a retrospective design and involved a limited number of patients. There is also the question of sensitivity and whether a prior screening of samples should be performed to determine which ones are to be processed for tNGS. Ultimately, the ultimate proof of the utility of ctDNA analysis for early detection of disease progression will be the demonstration of a patient survival benefit in prospective clinical studies.
Writing credits: Arlou Kristina Angeles and Holger Sültmann
1 Skoulidis, F. & Heymach, J. V. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer 19, 495-509, doi:10.1038/s41568-019-0179-8 (2019).
2 Gainor, J. F. et al. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov 6, 1118-1133, doi:10.1158/2159-8290.CD-16-0596 (2016).
3 Katayama, R. et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 4, 120ra117, doi:10.1126/scitranslmed.3003316 (2012).
4 Pailler, E. et al. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer. Clin Cancer Res 25, 6671-6682, doi:10.1158/1078-0432.CCR-19-1176 (2019).
5 Dietz, S. et al. Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. EBioMedicine 62, 103103, doi:10.1016/j.ebiom.2020.103103 (2020).
6 Mouliere, F. et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med 10, doi:10.1126/scitranslmed.aat4921 (2018).